| Quarter | Score |
|---|---|
| 2022-Q1 | 51.8 |
| 2022-Q3 | 70.8 |
| 2022-Q4 | 50.4 |
| 2023-Q1 | 48.9 |
| 2023-Q2 | 54.9 |
| 2023-Q3 | 48.9 |
| 2023-Q4 | 36.0 |
| 2024-Q1 | 74.2 |
| 2024-Q2 | 67.9 |
| 2024-Q3 | 57.7 |
| 2024-Q4 | 57.6 |
| 2025-Q1 | 58.7 |
| 2025-Q2 | 61.7 |
| 2025-Q3 | 61.7 |
| 2025-Q4 | 61.8 |
| 2026-Q1 | 61.8 |
| 2026-Q2 | 75.6 |
High consensus with active accumulation at an attractive valuation
Trading 12.6% below funds' estimated purchase price
2 of 18 tracked funds hold CMCSA. Avg conviction: 0.4%. Net adding. First tracked at $33.16 (current -12.6% vs tracked).
Greenlight Capital has 0.8% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Greenlight Capital | 0.8% | New Buy |
| Citadel Advisors | 0.0% | Add |